Introduction: Inhaled bronchodilators are the mainstay of the current management of COPD
at all stages of the disease, and are critical in the symptomatic management of asthma …

Bronchodilators remain central to the symptomatic management of chronic obstructive
pulmonary disease and asthma, and, for this reason and also because the patent protection …

Bronchodilators are central in the treatment of of airways disorders. They are the mainstay of
the current management of chronic obstructive pulmonary disease (COPD) and are critical in …

Educational aims To discuss fundamental questions relating to the use of bronchodilators
that can lead to an optimisation of their utilisation. To describe new bronchodilators that …

Inhaled bronchodilators, including long-acting muscarinic receptor antagonists (LAMA) and
long-acting β2-adrenoreceptor agonists (LABA), are the mainstay of pharmacological …

Because of the central role of bronchodilators in the treatment of respiratory diseases, there
is still considerable interest in finding novel classes of broncholytic drugs. It can be …

Introduction: It has long been known that combining short-acting muscarinic antagonists and
β2 agonists produces additive effects on the lung function of patients with chronic obstructive …

The Global Obstructive Lung Disease (GOLD) guidelines suggest the potential use of
combination bronchodilator therapy in patients with stage II or higher chronic obstructive …

Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease that is
characterized by progressive airway obstruction that, unlike asthma, is relatively insensitive …

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality,
and its prevalence is rising worldwide. Bronchodilators remain the cornerstone of COPD …